Penn Medicine Provider
Renal Electrolyte and Hypertension
Michael Rudnick, MD
5.0
(137)
Accepting new patients
Sees patients age 18 and up
Penn Renal Electrolyte and Hypertension University City
Schedule onlineCall 800-789-7366

About me

  • Chief, Section of Nephrology and Hypertension, Penn Presbyterian Medical Center
  • Associate Professor CE of Medicine

Education and training

  • Medical School: Drexel University Center City Hahnemann Campus
  • Residency: Hahnemann University Hospital
  • Fellowship: Hospital of the University of Pennsylvania
  • Fellowship: University of Pennsylvania

What my patients think about me

Average Rating
5.0

137 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

April 2025
5.0
5.0
always had a positive experience
April 2025
5.0
5.0
answer all my questions
April 2025
5.0
5.0
thorough, helpful, considerate; more than once asked if i had questions
April 2025
5.0
5.0
he's amazing and brilliant

Insurance accepted

My Locations

Learn about location

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Rudnick is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Rudnick MR., Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. [Review] [31 refs] , Reviews in Cardiovascular Medicine, 4 Suppl 5: 2003,S28-33

Wang A., Holcslaw T., Bashore TM., Freed MI., Miller D., Rudnick MR., Szerlip H., Thames MD., Davidson CJ., Shusterman N., Schwab SJ. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.[see comment] , Kidney International, 57(4): 2000,1675-80

Berns JS., Rudnick MR., Cohen RM., Bower JD., Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease , Kidney International, 56(1): 1999,253-60

Ermer JC., Boni JP., Cevallos WH., DeCleene S., Burghart P., Rudnick MR., Fruncillo RJ., Berns JS., Cohen RM. Bromfenac disposition in patients with impaired kidney function , Clinical Pharmacology & Therapeutics, 61(3): 1997,312-8

Rudnick MR., Berns JS., Cohen RM., Goldfarb S. Contrast media-associated nephrotoxicity. [Review] [150 refs] , Seminars in Nephrology, 17(1): 1997,15-26

Rudnick MR., Berns JS., Cohen RM., Goldfarb S. Contrast media-associated nephrotoxicity. [Review] [83 refs] , Current Opinion in Nephrology & Hypertension, 5(2): 1996,127-33

Berns JS., Haghighat A., Staddon A., Cohen RM., Schmidt R., Fisher S., Rudnick MR., Tomaszewski JE. Severe, irreversible renal failure after ifosfamide treatment. A clinicopathologic report of two patients , Cancer, 76(3): 1995,497-500

Rudnick MR., Goldfarb S., Wexler L., Ludbrook PA., Murphy MJ., Halpern EF., Hill JA., Winniford M., Cohen MB., VanFossen DB. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study , Kidney International, 47(1): 1995,254-61

Revicki DA., Brown RE., Feeny DH., Henry D., Teehan BP., Rudnick MR., Benz RL. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients , American Journal of Kidney Diseases, 25(4): 1995,548-54

Roth D., Smith RD., Schulman G., Steinman TI., Hatch FE., Rudnick MR., Sloand JA., Freedman BI., Williams WW Jr., Shadur CA., et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients , American Journal of Kidney Diseases, 24(5): 1994,777-84